Dr. Tanveer Ahmad’s expertise spans advanced cell and gene therapies, CRISPR diagnostics and therapeutics, stem cell biology, mitochondrial metabolism, and AI-driven biomedical innovation. He has led the development of next-generation CAR-T and CAR-NK platforms, including 3rd and 4th generation, allogeneic, mRNA-, and lentivirus-based constructs for hematologic malignancies, solid tumors, and autoimmune disorders. His contributions include CRISPR-Cas-based diagnostics such as saliva-based COVID-19 detection and EGFR mutation assays, as well as CRISPR-mediated genome editing strategies for universal CAR-T cells and genetic disorders like sickle cell disease.

With a strong foundation in stem cell biology, he has pioneered studies on mitochondrial transfer, necroptosis, and cellular senescence in fibrosis and degenerative diseases. Complementing these biological advances, he has developed AI-powered platforms for oral cancer prognosis, digital pathology, and antibody/CAR design.

Collectively, Dr. Tanveer Ahmad’s work integrates cutting-edge immunotherapy, molecular biology, and computational tools to drive translational innovations in precision medicine.